NEW ORLEANS -- Evolocumab (Repatha) reduced risk of a first major cardiovascular (CV) event in patients with diabetes but no known atherosclerosis in a substudy of the VESALIUS-CV trial.
The PCSK9 inhibitor cut relative risk by 31% compared with placebo whether looking at the composite of death from coronary heart disease, myocardial infarction (MI), or ischemic stroke (5-year Kaplan-Meier estimat...
The strongest version of this narrative is that evolocumab offers a significant clinical benefit for high-risk primary prevention patients with diabetes, even in the absence of known atherosclerosis. The data are robust, showing consistent reductions in major cardiovascular events and mortality, with LDL cholesterol levels driven to unprecedented lows. This challenges current guidelines, which recommend less aggressive lipid-lowering targets for primary prevention. The editorialists rightly high...